Financiado en parte por Sanofi, Tata Consultancy Services
An open-label, randomized, crossover study to evaluate the bioavailability of nanoemulsion versus conventional fat-soluble formulation of cholecalciferol in healthy participants
Marwaha RK, Verma M, Walekar A, Sonawane R, Trivedi C
Journal of orthopaedics · 5 citas
Etiquetas de revisión
Financiado por la industriaDatos neutrales que nuestra revisión registró sobre cómo se hizo este estudio. Describen el método, nunca si nos gusta el resultado.
Cómo se estudió
- Diseño
- Ensayo controlado aleatorizado (clasificado por nuestro filtro de IA)
- Estudiado en
- Personas
- Resultado principal
- Sin resultado de salud
Quién lo pagó
- Financiación
- Financiado por la industria
- Empresa
- Sanofi
- Empresa
- Tata Consultancy Services
Según 2 financiadores declarados.
Publicación
- Publicado
- 2022-11-03 · J Orthop · vol. 35 · págs. 64–68
- Editorial
- Elsevier BV
- Citado
- 10 citas · más que el 65% de estudios similares · 0.8× el promedio de su campo
- Referencias
- 30 trabajos
- Acceso
- Acceso abierto (revista híbrida) · CC-BY-NC-ND
- Áreas de investigación
- Advanced Drug Delivery Systems · Drug Solubulity and Delivery Systems · Protein purification and stability
- Palabras clave
- Bioavailability, Cmax, Cholecalciferol, Pharmacokinetics, Medicine, Crossover study, Pharmacology, Bioequivalence, Vitamin D and neurology, Internal medicine, Placebo
5 autores
- Raman Kumar Marwaha · autor de correspondencia
- Manish Verma🇮🇳Sanofi (India)
- Ajit Walekar🇮🇳Sanofi (India)
- Rakesh Sonawane🇮🇳Sanofi (India)
- Chirag .S. Trivedi🇮🇳Sanofi (India)
Resumen
El texto original del estudio, en el idioma en que se publicó.
Background
Nanoemulsion preparations of cholecalciferol available in the market claim to have better bioavailability than the conventional fat-soluble cholecalciferol. However, limited data are available in humans for such preparations. We, therefore, compared the relative bioavailability of two formulations of 60,000 IU cholecalciferol (nanoemulsion oral solution, water-miscible vitamin D3 [test] vs soft gelatin capsules [reference]) in healthy adult participants.
Methods
In this randomized, open-label, two sequence, single-dose, two-way crossover study (CTRI/2018/05/013839), Indian participants aged 18-45 years received single dose of nanoemulsion and capsule formulations, under fasting conditions. Blood samples collected over 120 h were assessed to determine cholecalciferol concentrations. Pharmacokinetic parameters (area under the concentration-time curve up to 120 h [AUC0-120h], maximum observed drug concentration [Cmax], time to reach maximum drug concentration [Tmax], terminal half-life [T½el], and terminal elimination rate constant [Kel]) were estimated using baseline corrected data and analyzed using analysis of variance.
Results
Among the 24 eligible participants, the relative bioavailability of nanoemulsion was significantly higher than the capsules by 36% (p = 0.0001) based on AUC0-120h. Similarly, Cmax of the nanoemulsion was significantly higher by 43% (p = 0.0001) than that of the capsules. The intra-participant variability for AUC0-120h and Cmax were 23.22% and 26.51%, respectively. The Tmax, T½el, and Kel were comparable for both the formulations. No adverse effects were noted with either of the two formulations.
Conclusions
Nanoemulsion oral solution of cholecalciferol showed a greater bioavailability compared with soft gelatin capsules, under fasting conditions, in healthy human participants.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial (CC BY-NC-ND).
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.